AgingResearch.NewsJoin free

APB-R3

Intervention

1 paper studies it3 findings

Across all fields, 1 paper: none in people yet, 1 in animals

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Korea Basic Science Institute and 3 more
  • Animals1

Outcomes

3

Senescence-associated secretory phenotype (SASP)

downin Rodentia1

1 study

  1. APB-R3 decreases senescence-associated secretory phenotype (SASP) in Rodentia.

    “Enhanced senescence associated secretory phenotype (SASP) markers in cholestatic liver disease were diminished by APB-R3 treatment.”

    AnimalsDDC diet-induced PSC rodent modelliver

    Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Senescence-associated secretory phenotype (SASP)

Liver fibrosis

downin Rodentia1

1 study

  1. APB-R3 decreases liver fibrosis in Rodentia.

    “Additionally, APB-R3 significantly ameliorated DDC diet-induced periductal fibrosis and transcriptional expressions of pro-fibrotic marker genes.”

    AnimalsDDC diet-induced PSC rodent modelliver

    Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Alkaline phosphatase

downin Rodentia1

1 study

  1. APB-R3 decreases alkaline phosphatase in Rodentia.

    “Administration of APB-R3 effectively attenuated key diagnostic parameters of PSC such as plasma ALP and GGT levels as well as bile acids levels.”

    AnimalsDDC diet-induced PSC rodent modelplasma

    Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Alkaline phosphatase

Latest

Related